Zafgen, Inc. (NASDAQ:ZFGN) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Monday.

Separately, Zacks Investment Research downgraded shares of Zafgen from a “buy” rating to a “hold” rating in a research report on Saturday, September 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $6.38.

Zafgen (NASDAQ:ZFGN) opened at 3.61 on Monday. The company’s 50 day moving average is $3.49 and its 200-day moving average is $3.86. Zafgen has a 52-week low of $2.89 and a 52-week high of $5.46. The company’s market capitalization is $99.21 million.

Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. During the same quarter in the previous year, the company earned ($0.55) EPS. Equities analysts anticipate that Zafgen will post ($2.23) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zafgen, Inc. (ZFGN) Stock Rating Upgraded by ValuEngine” was published by Daily Political and is owned by of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/10/17/zafgen-inc-zfgn-stock-rating-upgraded-by-valuengine.html.

In related news, Director Frances K. Heller bought 10,000 shares of the stock in a transaction on Friday, October 13th. The shares were acquired at an average price of $3.90 per share, for a total transaction of $39,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 21.20% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of ZFGN. Algert Global LLC bought a new position in Zafgen during the 2nd quarter valued at about $123,000. Parametric Portfolio Associates LLC lifted its stake in Zafgen by 55.8% during the 1st quarter. Parametric Portfolio Associates LLC now owns 28,832 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 10,327 shares during the period. Wells Fargo & Company MN lifted its stake in Zafgen by 1,290.3% during the 1st quarter. Wells Fargo & Company MN now owns 43,531 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 40,400 shares during the period. GSA Capital Partners LLP bought a new position in Zafgen during the 2nd quarter valued at about $259,000. Finally, LMR Partners LLP bought a new position in Zafgen during the 2nd quarter valued at about $299,000. Institutional investors and hedge funds own 48.52% of the company’s stock.

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.